Investors in the cell therapy industry are actively looking into solid tumours, autoimmune indications and novel engineering as the best place to allocate their money and resources.
In order for cell therapies to scale effectively, the industry is clamouring for standardisation around things like manufacturing and treatment administration.
Innovative, advanced therapies have enormous promise, but also come with a host of logistical problems that innovators underestimate at their own peril.